Fada Dipirona

Fada Dipirona may be available in the countries listed below.

Ingredient matches for Fada Dipirona

Metamizole

Metamizole is reported as an ingredient of Fada Dipirona in the following countries:

• Argentina

International Drug Name Search

Glumal

Glumal may be available in the countries listed below.

Ingredient matches for Glumal

Aceglutamide

Aceglutamide aluminium (a derivative of Aceglutamide) is reported as an ingredient of Glumal in the following countries:

• Japan

International Drug Name Search

Megarubicin

Megarubicin may be available in the countries listed below.

Ingredient matches for Megarubicin

Epirubicin

Epirubicin hydrochloride (a derivative of Epirubicin) is reported as an ingredient of Megarubicin in the following countries:

• Greece

International Drug Name Search

Trospi

Trospi may be available in the countries listed below.

Ingredient matches for Trospi

Trospium

Trospium Chloride is reported as an ingredient of Trospi in the following countries:

• Germany

International Drug Name Search

Fudixing

Fudixing may be available in the countries listed below.

Ingredient matches for Fudixing

Gatifloxacin

Gatifloxacin is reported as an ingredient of Fudixing in the following countries:

• China

International Drug Name Search

Clamoxyl

Clamoxyl may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Clamoxyl

Amoxicillin

Amoxicillin is reported as an ingredient of Clamoxyl in the following countries:

• Poland


• Portugal


• Switzerland


• Tunisia

Amoxicillin sodium salt (a derivative of Amoxicillin) is reported as an ingredient of Clamoxyl in the following countries:

• Belgium


• France


• Luxembourg


• Spain


• Switzerland

Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Clamoxyl in the following countries:

• Australia


• Austria


• Belgium


• France


• Germany


• Ireland


• Italy


• Luxembourg


• Norway


• Portugal


• South Africa


• Spain


• Switzerland


• United Kingdom


• Vietnam

Clavulanate

Clavulanic Acid potassium (a derivative of Clavulanic Acid) is reported as an ingredient of Clamoxyl in the following countries:

• Australia

International Drug Name Search

Plavix

Plavix is a brand name of clopidogrel, approved by the FDA in the following formulation(s):

PLAVIX (clopidogrel bisulfate - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: November 17, 1997
  
  Strength(s): EQ 75MG BASE
  


• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: September 20, 2007
  
  Strength(s): EQ 300MG BASE ^[RLD]

Has a generic version of Plavix been approved?

No. There is currently no therapeutically equivalent version of Plavix available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plavix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
  Patent 4,847,265
  Issued: July 11, 1989
  Inventor(s): Badorc; Alain & Frehel; Daniel
  Assignee(s): Sanofi
  The present invention relates to the dextro-rotatory enantiomer of Formula ##STR1## and its pharmaceutically acceptable salts with platelet aggregation inhibiting activity. The invention also relates to a process for the preparation of this compound starting from the racemate and the pharmaceutical compositions containing it.
  
  Patent expiration dates:
  
  
  • November 17, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • May 17, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for the secondary prevention of ischemic events
  Patent 5,576,328
  Issued: November 19, 1996
  Inventor(s): Herbert; Jean-Marc & Frehel; Daniel & Bernat; Andr e & Badorc; Alain & Savi; Pierre & Delebass ee; Denis & Kieffer; Gilles & Defreyn; Ghislain & Maffrand; Jean-Pierre
  Assignee(s): Elf Sanofi
  The invention relates to a new method for the secondary prevention of ischemic events comprising administering to a man in need thereof a therapeutically effective amount of a compound selected from clopidogrel and its pharmaceutically acceptable acid addition salts in association with a pharmaceutically acceptable carrier.
  
  Patent expiration dates:
  
  
  • January 31, 2014
    
    ✓ 
    Patent use: REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • July 31, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Polymorphic clopidogrel hydrogenesulphate form
  Patent 6,429,210
  Issued: August 6, 2002
  Inventor(s): André ; Bousquet & Bertrand; Castro & Jean; Saint-Germain
  Assignee(s): Sanofi-Synthelabo
  Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-&agr;-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate and a process for its preparation.
  
  Patent expiration dates:
  
  
  • June 10, 2019
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • December 10, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Polymorphic form of clopidogrel hydrogen sulphate
  Patent 6,504,030
  Issued: January 7, 2003
  Inventor(s): André ; Bousquet & Bertrand; Castro & Jean; Saint-Germain
  Assignee(s): Sanofi-Synthelabo
  Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-&agr;-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate and a process for its preparation
  
  Patent expiration dates:
  
  
  • June 10, 2019
    
    ✓ 
    Drug substance
  
  
  
  • December 10, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 6, 2014 - REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
  
  
  • November 6, 2014 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Plavix Consumer Information (Drugs.com)
• Plavix Consumer Information (Wolters Kluwer)
• Plavix Consumer Information (Cerner Multum)
• Plavix Advanced Consumer Information (Micromedex)
• Plavix AHFS DI Monographs (ASHP)
• Clopidogrel Consumer Information (Wolters Kluwer)
• Clopidogrel Consumer Information (Cerner Multum)
• Clopidogrel Advanced Consumer Information (Micromedex)
• Clopidogrel Bisulfate AHFS DI Monographs (ASHP)

Nivalin

Nivalin may be available in the countries listed below.

Ingredient matches for Nivalin

Galantamine

Galantamine is reported as an ingredient of Nivalin in the following countries:

• Georgia

Galantamine hydrobromide (a derivative of Galantamine) is reported as an ingredient of Nivalin in the following countries:

• Latvia


• Poland


• Russian Federation

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Nivalin in the following countries:

• Chile

International Drug Name Search